New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 10, 2014
10:27 EDTCANFCan-Fite CF102 approved for compassionate use in Israel
Can-Fite BioPharma announced that the Israeli Ministry of Health has approved the use of its drug CF102 for a patient with hepatocellular carcinoma, the most common form of liver cancer, under the country's Compassionate Use Program. The program allows doctor-initiated single-patient access to investigational treatments for innovative or investigational products not yet registered in any country worldwide. Can-Fite has also previously received Orphan Drug Designation from the U.S. FDA for CF102 in the treatment of advanced hepatocellular carcinoma.
News For CANF From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 23, 2015
07:05 EDTCANFCan-Fite signs distribution agreement for CF101 with Cipher Pharmaceuticals
Can-Fite BioPharma (CANF) announced it has signed a distribution agreement with Cipher Pharmaceuticals (CPHR) to distribute Can-Fite's lead drug candidate, CF101, for the treatment of moderate to severe psoriasis and rheumatoid arthritis in the Canadian market upon receipt of regulatory approvals. Under the terms of the distribution agreement, Cipher is making an upfront payment of C$1.65M to Can-Fite. In addition, the agreement provides that additional payments of up to C$2M will be received by Can-Fite upon the achievement of certain milestones plus royalty payments of 16.5% of net sales of CF101 in Canada. The agreement further provides that Can-Fite will deliver finished product to Cipher. The timeline to regulatory submissions to Health Canada will be determined by the completion of the remaining clinical trial program. to Global Data, the psoriasis treatment market was worth $3.6 billion in 2010 and is forecast to grow to $6.7B by 2018. According to independent business information provider visiongain, the global rheumatoid arthritis drug market is expected to generate revenues of $38.5B in 2017.
March 18, 2015
07:03 EDTCANFCan-Fite BioPharma completes development of commercial biomarker test
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use